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Mouseidentiﬁed in Drosophila as an essential component of the nuclear complex
required for canonical Wnt signaling. Here, we have investigated the role of the mammalian pygopus
ortholog, mPygo2, in pancreas development. We show that a null mutation of mPygo2 in mice causes
pancreas hypoplasia due to decreased progenitor cell proliferation after embryonic day (e) 12.5. During the
same time window, mPygo2-deﬁcient embryos begin to display a reduction in endocrine progenitors and
consequently a decrease in islet endocrine cell mass. Consistent with its function after e12.5, late-developing
endocrine cell types, such as beta, delta and PP cells, are speciﬁcally reduced, while the earlier-forming alpha
cells develop normally. We ﬁnd canonical Wnt signaling to be predominantly active in the mesenchyme at
the time when mPygo2 is required and demonstrate the dependence of Wnt signal transduction on mPygo2.
Furthermore, conditional deletion of mPygo2ﬂox allele in the pancreatic epithelium does not phenocopy the
defects in mPygo2-null mutants. Since mPygo2 is expressed in the pancreatic mesenchyme and the role of
the mesenchyme in epithelial progenitor cell expansion is well documented, our ﬁndings suggest an indirect
role for mPygo2 in epithelial growth and differentiation through regulation of mesenchymal signals.
Together, our data suggest a previously unappreciated role for mesenchymal Wnt signaling in regulating
pancreatic organ growth and cell differentiation.
© 2008 Elsevier Inc. All rights reserved.IntroductionIn mammals, the pancreas develops as separate ventral and dorsal
evaginations from the gut endoderm (Slack, 1995). As the dorsal and
ventral pancreatic buds appear at embryonic day (e) 9.5 and e10.5,
respectively, they each become surrounded by a cap of dense
mesenchyme. Subsequent proliferation of the epithelial progenitors
rapidly leads to formation of a branched epithelium that gives rise to
an endocrine and an exocrine tissue compartment. The pancreatic
endocrine compartment is comprised of glucagon-producing alpha,
the insulin-producing beta, the somatostatin-producing delta and
pancreatic polypeptide (PP)-producing cells that form sequentially
during development and cluster in so-called islets of Langerhans
shortly before birth. The exocrine acinar cells and ducts become
visible as distinct structures by about e14.5.versity, Xiamen, Fujian 361005,
r Medicine, Robert-Rössle-Str.
l rights reserved.All pancreatic cells arise from a common pool of pancreatic
epithelial progenitor cells that are marked by the transcription factor
Pdx1 (Gu et al., 2002). Expression of the transcription factors Ngn3 and
after e13.5, Ptf1a, subsequently restrict the developmental potential of
these pluripotent progenitors to an endocrine and exocrine fate,
respectively (Gu et al., 2002; Zhou et al., 2007). Since the pancreas has
limited capacity for adaptive growth, the ﬁnal size of the endocrine
and exocrine cell compartments at birth is largely determined by the
size of the highly proliferative pluripotent progenitor cell pool at the
pancreatic bud stage (Stanger et al., 2007). Mutations that affect
progenitor cell expansion early in development therefore commonly
result in peri- and postnatal pancreatic hypoplasia. Proliferation and
branching of the epithelial buds is controlled by both autonomous
cues in the epithelium as well as non-autonomous signals from the
surrounding mesenchyme (Murtaugh, 2007). When cultured in the
absence of mesenchyme, epithelial buds show minimal growth and
branching, which is restored upon recombination with mesenchyme
(Golosow and Grobstein, 1962; Wessells and Cohen, 1967). The
mesenchyme not only controls progenitor cell expansion, but also
promotes both endocrine and exocrine cell differentiation (Attali et al.,
2007; Li et al., 2004b; Scharfmann, 2000).
Previous studies have provided evidence that the Wnt signaling
pathway controls several aspects of pancreatic development. Early in
225N. Jonckheere et al. / Developmental Biology 318 (2008) 224–235development, the level of endodermal Wnt activity appears to control
the speciﬁcation of intestinal, liver and pancreatic fates in foregut
endoderm (Heller et al., 2002; McLin et al., 2007; Ober et al., 2006).
Gain- and loss-of-function studies in mice further indicate that during
pancreas morphogenesis, Wnt signaling is required for growth and
differentiation of the epithelium (Dessimoz et al., 2005; Heiser et al.,
2006; Murtaugh et al., 2005; Papadopoulou and Edlund, 2005; Wells
et al., 2007). Additional roles for Wnt signaling have been further
suggested during the perinatal and postnatal periods in islet
formation, islet cell proliferation and beta cell function (Fujino et al.,
2003; Kim et al., 2005; Rulifson et al., 2007).
While these studies have established that Wnt signaling is
important in the pancreas, the spatial and temporal pattern of Wnt
signal transduction and the speciﬁc requirements for Wnt activity in
the epithelium andmesenchyme have remained elusive. Notably, Wnt
signals can be intracellularly transduced through a so-called canonical
(Wnt/β-catenin) pathway or non-canonical (Wnt/Ca+ and Wnt/planar
cell polarity) pathways (Miller, 2002). The existence of parallel
pathways leaves ambiguity as to which intracellular signals control
the phenotype when Wnt signaling is perturbed at the Wnt ligand or
frizzled receptor level. As conditional deletion of the Wnt-effector β-
catenin in pancreatic epithelial progenitor cells causes defects in
progenitor cell expansion and exocrine cell differentiation, it has been
recently suggested that normal pancreas morphogenesis requires
canonical Wnt signaling autonomously in the epithelium (Murtaugh
et al., 2005; Wells et al., 2007). However, interpretation of the
mechanisms that underlie these phenotypic changes is complicated
by the fact that β-catenin also has Wnt-independent functions in cell
adhesion (Nelson and Nusse, 2004). To better understand the role of
canonical Wnt signaling in pancreas development, it is therefore
necessary to compare the effects of perturbing signal transduction at
several levels of the pathway.
In response to Wnt signaling, cytoplasmic β-catenin becomes
stabilized and enters the nucleus, where it functions in a complex
with Tcf/Lef transcription factors to activate Wnt target genes (Nelson
and Nusse, 2004). Recently, pygopus has been identiﬁed as an
additional core component of this complex in Drosophila and appears
to act as a nuclear anchor as well as coactivator for the β-catenin/Tcf/
Lef complex (Kramps et al., 2002; Krieghoff et al., 2006; Stadeli and
Basler, 2005; Thompson, 2004; Townsley et al., 2004a, 2004b).
Analysis of loss-of-function phenotypes in Drosophila and Xenopus
have shown that pygopus is an essential regulator of canonical Wnt
pathway responses (Belenkaya et al., 2002; Lake and Kao, 2003;
Parker et al., 2002; Thompson et al., 2002). The murine genome
contains two pygopus orthologs, pygopus 1 (mPygo1) and pygopus 2
(mPygo2). Consistent with the broader expression of mPygo2 than
mPygo1 during development and in adult tissues (Li et al., 2004a),
loss of mPygo2 function causes severe developmental defects in
various Wnt-dependent tissues, while mPygo1-deﬁcient mice exhibit
no apparent abnormalities (Li et al., 2007; Schwab et al., 2007; Song et
al., 2007). Therefore,mPygo2 appears to be the functionally important
ortholog in mice.
We show here that germline mutation of mPygo2 in mice causes
pancreatic hypoplasia and a speciﬁc defect in endocrine cell
differentiation. We ﬁnd that these defects result from decreased
proliferation of undifferentiated pancreatic progenitors and reduced
formation of endocrine progenitors after e13. Since the pancreas
develops normally in mice with a pancreatic epithelial-speciﬁc
deletion of mPygo2, our data suggest that mPygo2 controls mesench-
ymal signals required for pancreatic growth and differentiation.
Accordingly, we ﬁnd that canonical Wnt signaling is active in the
pancreatic mesenchyme at the time mPygo2mutant mice ﬁrst show a
phenotype and demonstrate dependence of this signal on mPygo2
function. Therefore, our results suggest that expansion and differ-
entiation of pancreatic epithelial progenitors requires canonical Wnt
signaling in the mesenchyme.Materials and methods
Mice
Mice carrying the null allele for mPygo2 were generated by Cre-mediated
recombination in ES cells (Li et al., 2007). For pancreas-speciﬁc deletion of mPygo2,
mice with a ﬂoxed mPygo2 allele (mPygo2ﬂox) (Li et al., 2007) were crossed with Pdx1-
Cre mice (Gu et al., 2002). In these experiments, mPygo2ﬂox/+; Pdx1-Cre or mPygo2+/−;
Pdx1-Cre littermates served as controls. PCR detection of the mPygo2ﬂox allele was
performed using primers forward 5′-AGC GTG TCT AAG GTC AGC CAG AGG TTT G-3′ and
reverse 5′-GTA AAG CGT TGG GGG AGA GGA GGA GGA C-3′. Axin2+/lacZ and BatGALmice
have been previously described (Lustig et al., 2002; Maretto et al., 2003).
All strains were maintained on a C57BL/6J background. Experiments were
performed with the approval of the UC Irvine Institutional Animal Care and Use
Committee protocol 2002-2420. Noon of the vaginal plug daywas considered as e0.5. To
label S-phase nuclei, some mice were injected with 50 g/g body weight of BrdU i.p.
45 min prior to sacriﬁce.
Tissue processing, immunohistochemistry and microscopy
Pancreata were ﬁxed in 4% paraformaldehyde in PBS for 4 h and immunoﬂuor-
escence was performed on 10 m cryopreserved or 7 m parafﬁn sections. Staining with
hematoxylin/eosin (Fisher) was performed according to the manufacturer's instruc-
tions. For immunostaining we followed a previously described protocol (Sander et al.,
1997). The following antibodies were used: rabbit anti-mPygo2 (1:500; Li et al.,
2007), guinea pig anti-insulin (1:5000; Linco), mouse anti-glucagon (1:50; Sigma),
mouse anti-somatostatin (1:3000; gift from Palle Serup, Hagedorn Institute), rabbit
anti-pancreatic polypeptide (1:2000; Dako), rabbit anti-amylase (1:500; Sigma),
armenian hamster anti-MUC1 (1:200; Lab Vision Corporation), mouse anti-β-catenin
(1:100; Sigma), guinea pig anti-Pdx1 (1:5000; gift from Chris Wright, Vanderbilt
University), guinea pig anti-Ngn3 (1:1000; Henseleit et al., 2005), rabbit anti-Ptf1a
(1:2000; gift from Helena Edlund, Umea University), mouse anti-BrdU (1:100;
Chemicon), rat anti-E-cadherin (1:2000; Sigma), rabbit anti-mPygo1 (1:3000; Schwab
et al., 2007), guinea pig anti-Pbx1 (1:400; Kim et al., 2002), guinea pig anti-Isl1
(1:5000; gift from Johan Ericson, Karolinska, Stockholm), rabbit anti-Sox9 (1:2000;
Chemicon). For immunohistochemistry, biotinylated anti-mouse or anti-guinea pig
IgG antibodies were used (1:200; Vector Laboratories). For immunoﬂuorescence,
antigen–antibody complexes were detected with Cy3- (1:2000; Jackson Laboratory)
or Alexa488-conjugated (1:2000; Molecular Probes) goat-raised secondary antibodies.
For detection of Pdx1, Ptf1a, Ngn3 and BrdU, antigen retrieval was performed by
incubation in pH 6.0 citrate buffer at 37 °C for 1 h. Glucagon and BrdU were detected
using the M.O.M. Immunodetection Kit (Vector Laboratories). TUNEL assays were
performed using the ApopTag® Plus Peroxidase In Situ Apoptosis Detection Kit
(Chemicon). Using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) as a
substrate, whole-mount X-gal staining was performed on either whole embryos or
isolated abdominal organs as described (Mombaerts et al., 1996). Images were
collected on a Zeiss Axioplan2 microscope with a Zeiss AxioCam driven by Zeiss
AxioVision v. 4.0 software.
Morphometric quantiﬁcation of cell numbers and area
For morphometric analysis, all pancreata were embedded in the same
orientation and serial sections were collected from the entire organ. Following
immunostaining, images from an entire pancreas section were acquired and if
necessary assembled in Adobe Photoshop. Cell counting and morphometric analysis
were performed on every ﬁfth section. E-cadherin was used to visualize the entire
pancreatic epithelial area and DAPI staining for detection of individual nuclei.
Mesenchymal cell area was measured by subtracting the epithelial cell area from the
total pancreatic area, including the mesenchyme. Morphometry was conducted using
Image-Pro Plus v. 5.0.1 (Media Cybernetics). The data are displayed as averages±
standard error of the mean. Statistical signiﬁcance was determined using Student's
t-test (Minitab v. 14.20).
RNA preparation and RT-PCR and real-time quantitative PCR
Total RNA from dissected pancreatic anlagen was extracted with the RNeasy kit
(Qiagen) and treated with DNAse. cDNAwas prepared by in vitro transcription using the
iScript cDNA synthesis kit (Biorad). The following primers were used for PCR: for
detection ofmPygo2 forward 5′-GGAGCG AAGAAA GTC CAA TAC-3′ and reverse 5′-GTT
AGA AGC GAC CAG ATGATC-3′ (75 bp product); for detection ofmPygo1 forward 5′-GTG
GTG ACA GTG GAC TGG ATG-3′ and reverse 5′-CTG AGT GAG TAA GGA CCA CAG-3′
(323 bp product); for detection of β-actin as an internal control forward 5′-TGT TAC CAA
CTG GGA CGA CA-3′ and reverse 5′-GGG GTG TTG AAG GTC TCA AA-3′. Ampliﬁcation
was performed for 35 PCR cycles.
For quantitative RT-PCR analysis, all transcripts were ampliﬁed with 1× SYBR Green
PCR master mix (Applied Biosystems), as described previously (Kioussi et al., 2006).
Listed 5′ to 3′, primer sequences were as follows: mPygo1 forward: CCATCGCGCTGAA-
GAGAGTTA; mPygo1 reverse: GTGTGTTGGCCTTGCGTTTT; mPygo2 forward:
AAGGCCGGTCTGCAAATGAA; mPygo2 reverse: GTTAGAAGCGACCAGATGATCC; Axin2
forward: TGACTCTCCTTCCAGATCCCA; Axin2 reverse: TGCCCACACTAGGCTGACA.
Fig. 1.mPygo2 is expressed in the pancreatic epithelium and mesenchyme. Immunoﬂuorescence detection of mPygo2 protein (red) at e10.5 (A–C), e12.5 (D–I), e15.5 (J–O) and e18.5
(P–R). (A–C) At e10.5, mPygo2 (B and C) colocalizes with the progenitor cell marker Pdx1 (green in panels A and C) in both dorsal and ventral pancreatic anlage. (D–F) At e12.5,
colocalization of mPygo2 (E, H) with Pdx1 (green in panels D, G) persists in pancreatic epithelial cells. mPygo2 is also abundantly detected in the mesenchyme surrounding both
pancreatic anlagen at e10.5 (B) and e12.5 (E). (G–I) β-Catenin (green in panels G and I) is coexpressed with mPygo2 (H and I) in the epithelium and the mesenchyme. (J–L) At e15.5,
most E-cadherin+ epithelial cells (green in panels J and L) still express mPygo2 (K and L). The interstitial mPygo2+, but E-cadherin-negative cells (arrowheads in panel L) suggest
persistent mesenchymal expression of mPygo2 at e15.5. (M, N) Immunostaining for amylase (green in panel M) and mPygo2 (red in panel N) on adjacent sections demonstrates
localization of mPygo2 to the same cluster of cells that expresses amylase (arrowheads in panels M and N). (O) mPygo2 (red) and Pdx1 (green) are co-expressed in epithelial cell
clusters that resemble forming exocrine acini (inset in panel O). (P–R) At e18.5, mPygo2 expression is restricted tomucin 1 (MUC1)+ ductal cells (inset in panel P) and interstitial cells,
but absent from insulin+ (ins, inset in panel Q) or glucagon+ (glc, inset in panel R) cells. VP, ventral pancreas; DP, dorsal pancreas; scale bars=50 μm.
226 N. Jonckheere et al. / Developmental Biology 318 (2008) 224–235
227N. Jonckheere et al. / Developmental Biology 318 (2008) 224–235Results
Expression pattern of mPygo2 in the developing pancreas
Todetermine the domains ofmPygo2 expression,weperformed co-
immunoﬂuorescence analyseswith an anti-mPygo2 speciﬁc antiserum
in conjunction with antibodies against various pancreatic markers on
embryonic pancreas sections. Speciﬁcity of the anti-mPygo2 antibody
was demonstrated by absence of immunostaining in pancreas from
mPygo2-null mutant embryos (Supplementary Figs. 1D–F). Similar toFig. 2. Deletion ofmPygo2 in mice results in pancreas hypoplasia. (A, B) Examination of gross
the ventral pancreas (VP) inmPygo2-null mutants. The dashed yellow line indicates the separ
size in mPygo2−/− embryos correlates with a signiﬁcant reduction in the ratio between pancr
staining of parafﬁn sections from control (D) or mPygo2−/− (E) pancreas reveals no alterat
compartments. (F–H) At e15.5, mPygo2-deﬁcient embryos show a similar reduction in pancr
n=6). (I–N) The pancreatic epithelium was visualized by Pdx1 immunoﬂuorescence staining
(K, N). The dorsal and ventral pancreatic epithelial area in mPygo2-null mutants is reduced a
n=5), but normal at e12.5 (N; n=3). Scale bar=50 μm.previously analyzed tissues (Li et al., 2007; Schwab et al., 2007),
pancreatic mPygo2 expression was exclusively nuclear at all stages
(Fig. 1). Between e10.5 and e12.5, when the pancreatic epithelium is
still largely undifferentiated, mPygo2 broadly co-localized with the
pancreatic epithelial progenitor cell marker Pdx1 throughout the
ventral and dorsal pancreatic anlage (Figs. 1A–F, data not shown). The
level of mPygo2 expression varied between cells in the epithelium,
with some cells expressing high and others low levels of mPygo2.
Strong mPygo2 immunoreactivity was also found in mesenchymal
cells surrounding the ventral and the dorsal pancreatic anlage at e10.5pancreas morphology at e18.5 reveals a reduction of both the dorsal pancreas (DP) and
ation between dorsal and ventral pancreas. (C) The morphological reduction in pancreas
eas weight and total body weight at e18.5 (pb0.05; n=7). (D, E) Hematoxylin and eosin
ion of global pancreas histology and normally developed endocrine and exocrine cell
eas size (F, G) and in pancreas weight to body weight ratio (H) as seen at e18.5 (pb0.05;
(red in panels I, J and L, M) and the immunopositive area morphometrically quantiﬁed
t e13.5 (K; pb0.02 for ventral pancreas; not statistically signiﬁcant for dorsal pancreas;
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effector β-catenin was also expressed in both the pancreatic
epithelium and surrounding mesenchyme (Figs. 1G–I). Consistent
with previous reports (Heiser et al., 2006), nuclear localization of β-
cateninwas not observed. At e15.5, mPygo2 expression in E-cadherin+
cells suggested persistence of the epithelial mPygo2 expression (Figs.
1J–L). In addition to its epithelial expression, the presence of
scattered E-cadherin-negative/mPygo2+ interstitial cells indicated
persistent expression of mPygo2 also in the mesenchyme (Fig. 1L,
arrowheads). The staining intensity of mPygo2 in the epithelium
varied between different cell types. While newly differentiated beta
cells, characterized by high levels of Pdx1 expression, showed weak
mPygo2 immunoreactivity (Fig. 1O), strong expression was seen in
the forming acinar compartment (Figs. 1M–O). Scattered mPygo2+
mesenchymal cells were also detected in late gestation (Figs. 1P–R).
At e18.5, mPygo2 was no longer found in the acinar and endocrine
compartments (Figs. 1Q, R), but persisted in a subset of ductal cells
(Figs. 1P, R).
In contrast to mPygo2, mPygo1 was predominantly localized to the
pancreatic mesenchyme, but scattered Pdx1+ epithelial cells expres-
sing mPygo1 were also found (Supplementary Figs. 1J–H). In the
absence of mPygo2 activity, the overall expression pattern (Supple-
mentary Figs. 1K–M) and mRNA levels (Supplementary Fig. 1O) of
mPygo1 were unchanged. However, the number of epithelial cells
expressing mPygo1 appeared to be reduced in mPygo2-deﬁcient mice
(Supplementary Fig. 1M). Different from mPygo2, mPygo1 expression
was only transiently detected in the pancreas and no longer found
after e15.5 (Supplementary Figs. 1G, N).
Reduced pancreas size in mPygo2−/− embryos
To determine whether pancreas development is dependent on the
function of mPgyo2, we analyzed pancreata from mPygo2−/− embryos
at e18.5. The perinatal lethality associated with mPygo2-null muta-
tions precluded studies in postnatal mice (Li et al., 2007; Schwab et al.,
2007). Inspection of pancreas morphology revealed a marked
reduction in organ size in mPygo2-deﬁcient embryos (Figs. 2A, B).Fig. 3. Pancreatic hypoplasia inmPygo2−/−mice correlates with decreased epithelial cell prolif
Pdx1 (green in panels A and B). Morphometric quantiﬁcation of the number of glucagon+ ce
premature differentiation of glucagon+ cells in mPygo2−/− pancreas at e13.5 (C; n=3). (D–F)
panels D and E) and the progenitor cell marker Sox9 (green in panels D and E) reveals a ∼2
mPygo2−/− mutants at e13.5 (F; pb0.01; n=5). Scale bar=50 μm.The reduction was evident in both the duodenal portion of the
pancreas, which is derived from the ventral pancreatic anlage, as well
as the splenic portion, which originates from the dorsal anlage. To
exclude the possibility that the reduced pancreatic size is a mere
consequence of the 15–20% reduction in body weight of neonatal
mPygo2−/− embryos (Li et al., 2007), we normalized pancreatic weight
to the total body weight of the embryo. The ratio of pancreatic weight
to body weight showed a statistically signiﬁcant ∼20% reduction in
mPygo2−/− embryos compared to their wild type littermates (Fig. 2C).
Histological analysis of pancreas sections revealed grossly normal
exocrine and endocrine cell compartments (Figs. 2D, E).
To determine the origin of pancreas hypoplasia in mPygo2-
deﬁcient embryos, we examined whether a reduction in pancreatic
size is already present at earlier developmental time points. At e15.5,
when the overall size and weight of mPygo2−/− embryos is indis-
tinguishable from wild type littermates (data not shown), the ventral
and dorsal pancreas showed a similar size reduction as observed at
e18.5 (Figs. 2F–H). Prior to e15.5, we assessed pancreatic size by
separate quantitative morphometric measurements of the ventral and
dorsal pancreatic epithelial area. At e13.5, the pancreatic epithelium in
mPygo2−/− embryos showed less branching and a signiﬁcant reduction
in size (Figs. 2I–K). At e12.5, however, no difference was found
betweenmPygo2−/− and wild type embryos (Figs. 2L–N). Thus,mPygo2
is ﬁrst required for growth and branching of the pancreatic epithelium
after e12.5.
To reveal the mechanism that underlies impaired pancreatic
growth in mPygo2−/− embryos, we studied whether mPygo2 controls
the timing of cell differentiation, cell proliferation or cell survival.
During pancreas development, major cell differentiation of both the
exocrine and endocrine compartments does not occur until after
e13.5. With the exception of occasional insulin-producing cells,
glucagon-expressing cells are the only cell type that differentiates
between e10.5 and e13.5. To assess whether the diminished size of the
pancreas in mPygo2-deﬁcient embryos results from depletion of the
pancreatic progenitor cell pool due to premature cell cycle exit and
differentiation, we quantiﬁed the number of glucagon+ cells in relation
to the number of Pdx1+ pancreatic progenitors between e10.5 anderation. (A–C) Immunoﬂuorescence staining for glucagon (glc, red in panels A and B) and
lls in relation to the total area occupied by Pdx1+ pancreatic progenitor cells reveals no
By contrast, quantiﬁcation of the number of cells co-immunopositive for BrdU (red in
0% decrease in the proliferative rate of ventral and dorsal pancreatic progenitor cells in
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embryos and wild type littermates (Figs. 3A–C, data not shown),
suggesting that absence of mPygo2 is not associated with premature
cell differentiation. This conclusion was further supported by the
ﬁnding that insulin+ or exocrine cells also do not differentiate
prematurely (data not shown). To determine whether absence of
mPygo2 affects pancreatic cell proliferation, we next compared the
number of BrdU-incorporating cells inmPygo2−/− and control embryos
at e13.5, which is the time point when the epithelial size reduction is
ﬁrst evident in mPygo2−/− embryos. mPygo2-null mutants showed a
consistent 20–25% reduction in the proliferative rate of Sox9+
progenitor cells in both the ventral and the dorsal pancreatic anlage
(Figs. 3D–F). Signiﬁcantly, no difference was observed at e12.5, when
the epithelium is still normal in size (data not shown). Since apoptotic
cells were rarely seen in the pancreatic epithelium or mesenchymeFig. 4. Loss of mPygo2 activity affects formation of late-born endocrine cells. (A–C) Insulin imm
the insulin+ area over total pancreatic epithelial area at e15.5 reveals a 50% reduction of bet
(D–F) Similar analysis for the glucagon+ (red in panels D and E) cell area at e15.5 shows no r
pancreatic polypeptide+ areas (red in J and K) at e18.5 are similarly reduced as the insulin+ are
and N) is similar in e15.5 control and mPygo2-null mutant embryos (O; n=3). Scale bar=50and no difference was found betweenmPygo2−/− and control embryos
(Supplementary Figs. 2A, B), our ﬁndings suggest that mPygo2 con-
trols pancreatic growth by ensuring proliferation of undifferentiated
pancreatic progenitor cells after e13. As the size of the pancreatic
progenitor cell pool has recently been shown to dictate ﬁnal organ size
(Stanger et al., 2007), this early function of mPygo2 in progenitor cell
proliferation most likely also accounts for the reduced pancreas size in
neonatal mPygo2−/− mice.
mPygo2 controls endocrine but not exocrine cell formation
To assess a potential role for mPygo2 in pancreatic cell differentia-
tion, we compared the size of the endocrine and exocrine cell
compartments in mPygo2-null mutant embryos to their littermate
controls. Morphometric analysis of the insulin- and glucagon-unoﬂuorescence staining (green in panels A and B) andmorphometric quantiﬁcation of
a cells in mPygo2-deﬁcient pancreas compared to control littermates (C; pb0.05; n=3).
eduction in alpha cells (F; n=3). (G–L) The somatostatin+ (green in panels G and H) and
a (I, L; pb0.01; n=3). (M–O) The relative area occupied by amylase+ cells (red in panels M
μm.
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reduction in beta cells, but not in alpha cells in mPygo2−/− mutants at
e15.5 and at birth (Figs. 4A–F, data not shown). A similar reduction as
was observed for beta cells was also seen for somatostatin- and PP-
producing cells (Figs. 4G–L). Unlike the endocrine cell compartment,
the amylase+ acinar cell compartment was not affected by mPygo2-
deﬁciency at both ages (Figs. 4M–O, data not shown). As assessed by
histology and immunoﬂuorescence for DBA and mucin, the ductal cell
compartment developed normally in mPygo2−/− mice (data not
shown).
The numbers of Ptf1a+ progenitors, which become restricted to an
exocrine fate around e13.5 (Zhou et al., 2007), appeared slightly
increased inmPygo2−/− embryos (Figs. 5A–C). However, this difference
did not reach statistical signiﬁcance (Fig. 5C). To determine whether
the reduction in endocrine cells can be attributed to a lower rate of cell
differentiation, we analyzed the number of Ngn3+ endocrine progeni-
tors. The 50% reduction in beta cells in mPygo2−/− embryos (Fig. 4C)
was indeed preceded by a 40–50% reduction in endocrine progenitors
in the ventral and dorsal pancreatic anlage at e13.5 (Figs. 5D–F).
Notably, Ngn3+ cell numbers were normal in mPygo2−/− mutants at
e12.5 (data not shown). As a recent study has demonstrated that beta,
delta and PP cells are the major endocrine cell types to arise from
Ngn3+ progenitors after e13 (Johansson et al., 2007), the selective
reduction in these cell types in Pygo2−/−mutants may be explained by
a speciﬁc requirement for mPygo2 in the generation of endocrine
progenitors during this time window. Combined, our data show that
mPygo2 has a critical role for progenitor cell proliferation and
endocrine cell genesis after e12.5.
Wnt signaling is mainly active in the pancreatic mesenchyme when
mPygo2 is required
In Drosophila, pygopus has been shown to be an obligatory
regulator of Wnt signal transduction (Belenkaya et al., 2002; Kramps
et al., 2002; Parker et al., 2002; Stadeli and Basler, 2005; Thompson
et al., 2002; Thompson, 2004; Townsley et al., 2004a). To determine
whether a similar genetic interaction exists betweenmPygo2 andWnt
signaling in the mammalian pancreas, we analyzed the spatial and
temporal proﬁle of Wnt signal transduction during pancreas devel-
opment. A similar analysis has been previously performed in pancreasFig. 5. Loss of mPygo2 activity affects formation of endocrine progenitors after e13. (A–C) Co
embryos show no reduction in Ptf1a+ progenitor cells (red in panels A and B) at e13.5 (C; n
panels D and E) is 50% reduced in mPygo2−/− embryos at e13.5 (F; pb0.01; n=5). Scale bar=from e14.5 embryos and older, but not at earlier embryonic stages
(Dessimoz et al., 2005). To identify sites of active Wnt signaling in
mouse tissue, a number of different lacZ-based reporter strains have
been developed. One of these strains is based on the expression of
Axin2, which is exclusively expressed at sites of Wnt signal transduc-
tion (Jho et al., 2002; Lustig et al., 2002). In embryos that express lacZ
under control of the Axin2 locus, β-galactosidase (β-gal) activity was
mainly conﬁned to the undifferentiated pancreatic epithelium and
early differentiated glucagon+ cells, but was also detected in scattered
cells in the surrounding mesenchyme at e10.5 (Fig. 6A). At e13.5,
the pattern was reversed, evidenced by abundant lacZ expression
in the mesenchyme and only occasional lacZ+ cells in the epithelium
(Fig. 6B). The predominant localization of β-gal activity to the mesen-
chyme persisted at e15.5 (Fig. 6C). Consistent with the previous study
(Dessimoz et al., 2005), few glucagon+ cells also showed detectable
lacZ expression (Figs. 6B and C, inset). At e18.5, lacZ+ cells were found
in the pancreatic ducts, but were largely absent from the endocrine
and exocrine compartments (Figs. 6D, E). Since reporter mouse lines
for Wnt activity have been shown to not necessarily monitor all sites
of Wnt signal transduction, we conﬁrmed our results in BatGAL mice,
in which expression of a lacZ transgene is controlled by tandem
repeats of Wnt-dependent Tcf/Lef transcription factor binding sites
(Maretto et al., 2003). The sites of β-gal activity in the developing
pancreas of BatGAL embryos largely mirrored those identiﬁed in
Axin2+/lacZ mice (Figs. 6F–J). The overall number of lacZ+ pancreatic
cells, however, was smaller in BatGAL mice at all stages. In the adult
pancreas, β-gal activity was not detected in either Wnt reporter strain
(data not shown).
To address whether loss of mPygo2 affects Wnt signaling, we
crossed the BatGAL transgene into the mPygo2-null mutant back-
ground and assayed for β-gal activity in the pancreas. Previous studies
have shown that in many tissues deletion of mPygo2 results in a
reduction but not complete absence of BatGAL transgene expression
(Li et al., 2007; Schwab et al., 2007). After a 4-h incubation in X-Gal
staining solution, we consistently observed lacZ+ cells in wild type
pancreas, but no signal was detected in pancreas of mPygo2−/−
embryos (Figs. 7A, B). However, after more than 12 h in X-Gal staining
solution, we occasionally observed lacZ+ cells also in mPygo2-null
mutants (data not shown). These ﬁndings indicate that loss of
pancreatic mPygo2 activity results in a drastic reduction, but notnsistent with normal development of the exocrine compartment, mPygo2-null mutant
=4). (D–F) By contrast, the relative number of Ngn3+ endocrine progenitor cells (red in
50 μm.
Fig. 6. The canonical Wnt signaling pathway is predominantly active in the pancreatic mesenchyme at the timemPygo2 activity is required in pancreas development. X-gal staining of
pancreata from Axin2+/lacZ (A–E) or BatGAL embryos (F–J) and subsequent immunoperoxidase detection of glucagon (glc, panels A–D and panels F–I) or insulin (ins, panels E and J) on
parafﬁn sections. The dashed red line in panels A, B, F, G demarcates the outer margin of the pancreatic epithelium. At e10.5, β-galactosidase (β-gal) activity is predominantly found in
the pancreatic epithelium, but occasional β-gal+ cells are also detected in the surroundingmesenchyme of bothAxin2+/lacZ (A) and BatGAL embryos (F). Someoverlap betweenβ-gal and
glucagon expression is observed (inset in panels A, B). At e13.5, mesenchymal cells are uniformly β-gal+ in Axin2+/lacZmice (B), while scattered β-gal activity is detected throughout the
mesenchyme of BatGALmice (G). In both Axin2+/lacZ and BatGAL embryos, pancreatic epithelial cells are rarely β-gal+ at e13.5, and those that are occasionally express glucagons (inset in
panels B, G). With the exception of occasional epithelial cells, some of which are glucagon/β-gal co-positive in Axin2+/lacZ mice (inset in panels C, H), the predominantly
mesenchymal location of β-gal activity persists at e15.5 in both reporter strains (C, H). At e18.5, β-gal activity is largely absent from glucagon+ (D, I) and insulin+ cells (E, J) and
predominantly localized to the pancreatic ducts in both Axin2+/lacZ and BatGAL embryos (arrowheads in panels D, I). DP, dorsal pancreatic epithelium; i, islet. Scale bar=50 μm.
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supported by the observation that the mRNA of Axin2 was reduced,
but not absent in mPygo2-deﬁcient pancreata (Supplementary
Fig. 1O). Consistent with observations in other tissues, mPygo2
therefore appears to function as a modulator of Wnt signaling in the
developing pancreas.
Pancreatic growth and cell differentiation depends on mPygo2 activity in
the mesenchyme
Since the mesenchyme is known to stimulate proliferation of
pancreatic progenitor cells, we considered the possibility that theeffects of germline mPygo2 deletion on epithelial growth and
differentiation are non-autonomous and mediated by mesenchymal
mPygo2 function. To distinguish between autonomous functions for
mPygo2 in the epithelium and non-autonomous functions in the
mesenchyme, we selectively ablated mPygo2 in pancreatic epithelial
precursors. Previous studies have shown that Pdx1-Cre transgenic
mice efﬁciently target ventral and dorsal pancreas precursors at the
time of pancreatic bud formation (Gu et al., 2002; Heiser et al., 2006;
Seymour et al., 2007). Consistent with these reports, we observed
complete recombination in progenitors of both pancreatic anlagen by
e9.5, when Pdx1-Cre mice were crossed to the R26R (Soriano, 1999)
reporter mouse strain (data not shown). To ablate mPygo2 in
Fig. 7. mPygo2 deletion reduces transduction of canonical Wnt signals in the pancreas.
Pancreatic sections from X-gal stained mPygo2+/+; BatGAL (A) or mPygo2−/−; BatGAL (B)
embryos at e12.5. mPygo2-deﬁciency results in absence of β-galactosidase (β-gal)+ cells
in both the pancreatic epithelium and mesenchyme. The dashed red lines demarcate
the outer margin of the pancreatic epithelium. Scale bar=50 μm.
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delete a ﬂoxedmPygo2 (mPygo2ﬂox) allele (Fig. 8A). Analysis of pancreata
from mPygo2ﬂox/−;Pdx1-Cre (mPygo2Δpan/−) embryos revealed efﬁcient
pancreatic recombination of the mPygo2ﬂox allele (Fig. 8B). mPygo2Fig. 8. Almost complete absence of epithelial mPygo2 after Pdx1-Cre-mediated recombinatio
of the forward and reverse primers for detection of the unrecombinedmPygo2ﬂox allele are in
mPygo2ﬂox/−; Pdx1-Cre andmPygo2ﬂox/−mice. While also readily detectable in DNA frommPyg
frommPygo2ﬂox/−; Pdx1-Cre pancreas at e15.5. The faint band ampliﬁed frommPygo2ﬂox/−;Pdx
cells in e15.5 pancreas that are not targeted by the Pdx1-Cre transgene, but can also be expla
mPygo2 (green) and Pdx1 (red) on pancreas sections of mPygo2ﬂox/−;Pdx1-Cre and control l
control embryos, mPygo2 is selectively absent from the epithelium inmPygo2ﬂox/−;Pdx1-Cre eimmunoreactivity was almost completely absent from the pancreatic
epithelium, but maintained in the surrounding mesenchyme (Figs. 8C–
H). A few mPygo2+ cells, however, were occasionally observed in the
epithelium (Fig. 8H). Unlike mPygo2−/− mice, mPygo2Δpan/− embryos
showed a pancreas of normal size and weight at both e15.5 and e18.5
(Figs. 9A–C; data not shown). Similarly, at e13.5 the overall size and
branching pattern of the ventral and dorsal pancreatic epithelium was
indistinguishable between mPygo2Δpan/− embryos and control litter-
mates (Figs. 9D–F). Thus, epithelial-speciﬁc deletion ofmPygo2 does not
phenocopy the pancreatic hypoplasia observed inmPygo2-null mutant
mice. Likewise, in contrast tomPygo2-nullmutants (Figs. 4A–C), beta cell
mass in mPygo2Δpan/− embryos was equivalent to control littermates
(Figs. 9G–I). We considered the possibility that mPygo2 is required for
expansion and maintenance of the pancreatic mesenchyme, which
would explain the lack of epithelial growth. However, themesenchymal
compartmentwas of normal size inmPygo2−/− embryos (Supplementary
Figs. 2C–F), suggesting that mPygo2 is not required for formation of the
pancreatic mesenchyme. Consistent with this notion, the expression of
Isl1 and Pbx1 was not affected bymPygo2 deletion (Supplementary Fig.
3). Together, these ﬁndings suggest that mPygo2 controls expansion of
pancreatic progenitors and endocrine cell formation by a non-n of themPygo2ﬂox allele. (A) InmPygo2ﬂoxmice, exon 3 is ﬂanked by loxP sites. Positions
dicated. (B) The unrecombinedmPygo2ﬂox allele is equally detected in tail tip DNA from
o2ﬂox/− pancreas after 30 PCR cycles, the unrecombinedmPygo2ﬂox allele is not ampliﬁed
1-Cre pancreas after 33 PCR cycles most likely results from the presence of mesenchymal
ined by residual unrecombined epithelial cells. (C–H) Immunoﬂuorescence detection of
ittermates at e13.5. While mPygo2 is expressed in the epithelium and mesenchyme of
mbryos. Residual mPygo2+ cells are rarely observed in the epithelium. Scale bar=50 μm.
Fig. 9.Normal pancreas development inmPygo2ﬂox/−;Pdx1-Cremice. (A, B) Examination of gross pancreasmorphology at e18.5 reveals a normal sized dorsal pancreas (DP) and ventral
pancreas (VP) inmPygo2ﬂox/−;Pdx1-Cre (mPygo2Δpan/−) embryos. The dashed yellow line indicates the separation between dorsal and ventral pancreas. (C) Likewise, the ratio between
pancreas weight and total body weight is similar inmPygo2Δpan/− and control embryos at e15.5 (n=5). (D–F) The pancreatic epitheliumwas visualized by Pdx1 immunoﬂuorescence
staining (red in panels D, E). Morphometric quantiﬁcation shows normal dorsal and ventral pancreatic epithelial areas in mPygo2Δpan/− embryos at e13.5 (F; n=4). (G–I) Insulin
immunoﬂuorescence staining (green in panels G and H) and morphometric quantiﬁcation of the insulin (ins)+ area over total pancreatic epithelial area at e15.5 reveals normal beta
cell formation in mPygo2Δpan/− embryos (I; n=6). Scale bar=50 μm.
233N. Jonckheere et al. / Developmental Biology 318 (2008) 224–235autonomous mechanism, possibly by regulating signals from the
mesenchyme.
Discussion
In this study, we have deﬁned the role of pygopus, a nuclear
component of the canonical Wnt signaling pathway, in pancreas
development. We show that mPygo2 is required for pancreatic
progenitor cell proliferation and endocrine cell neogensis. While
mPygo2 is expressed in both the pancreatic epithelium and mesench-
yme, we identify the mesenchyme as a predominant site of canonical
Wnt signaling around e13 and show that absence of mPygo2 impairs
transduction of this signal. Our ﬁnding that conditional deletion of
mPygo2 in just the epithelium fails to phenocopy the null mutant
defects suggests a role for mesenchymal Wnt signaling in pancreas
organogenesis.
Does mPygo2 function in the Wnt signaling pathway?
Genetic studies in Drosophila have identiﬁed pygopus as an
obligatory component of the wingless signaling pathway (Belenkaya
et al., 2002; Kramps et al., 2002; Parker et al., 2002; Stadeli and Basler,
2005; Thompson et al., 2002; Thompson, 2004; Townsley et al.,
2004a). Recent studies of pygopus function in mammals, however,
suggest that complete loss of pygopus activity reduces, but does not
completely abrogate Wnt signaling (Li et al., 2007; Schwab et al.,
2007). Though deletion of mPygo1 and mPygo2 affects the develop-
ment of many Wnt-dependent tissues, the developmental defectscaused by absence of pygopus activity in mice are notably milder than
those observed when Wnt signal transduction is completely blocked
(Li et al., 2007; Schwab et al., 2007; Song et al., 2007). Some Wnt-
dependent phenotypes, such as the defect in early embryonic axis
formation as a result of β-catenin deﬁciency or the defect in intestinal
stem cell proliferation caused by loss of Tcf4 activity (Haegel et al.,
1995; Huelsken et al., 2000; Korinek et al., 1998), are not phenocopied
by the combined deletion of both murine pygopus orthologs (Li et al.,
2007; Schwab et al., 2007; Song et al., 2007). These ﬁndings have led
to the suggestion that Pygo1 and Pygo2 are not obligatory for
canonical Wnt signaling in mammals, but rather function as
modulators of Wnt signaling intensity. Our observation that even
though signiﬁcantly reduced, BatGAL reporter activity and Axin2
mRNA were still detectable in mPygo2-deﬁcient pancreas supports
the idea that mPygo2 also functions as a Wnt modulator during
pancreas development. Remaining Wnt activity in the absence
of mPygo2 may also explain why mPygo2Δpan/− mice do not display
pancreatic hypoplasia and defects in acinar cell development,
as observed in mice after Pdx1-Cre-mediated β-catenin ablation
(Dessimoz et al., 2005; Murtaugh et al., 2005; Wells et al., 2007).
Alternatively, compensation of mPygo1 for mPygo2 function
could account for the difference in phenotype caused by pancreatic
β-catenin and mPygo2 ablation. We consider this possibility highly
unlikely, as we detected mPygo1 protein predominantly in the
mesenchyme and only in scattered epithelial cells. Moreover,
mPygo1-deﬁcient mice are indistinguishable from wild type mice
and no apparent genetic cooperativity has been observed between
Pygo1 and Pygo2 in mice (Schwab et al., 2007; Song et al., 2007).
234 N. Jonckheere et al. / Developmental Biology 318 (2008) 224–235Notably, since β-catenin is known to haveWnt-independent functions
in cell adhesion (Nelson and Nusse, 2004), it is also possible that the
reported defects in β-catenin-deﬁcient pancreata are not dependent
on Wnt signaling. To obtain a more complete understanding of Wnt
function in the pancreas, it will be necessary to study the effects of
inactivation of additional Wnt signaling components on pancreas
development.
mPygo2 function in pancreas development
Starting at e13.5, we found that mPygo2-deﬁcient pancreata are
signiﬁcantly smaller than wild type controls. Our data show that a
reduced proliferation rate of pancreatic progenitors and not increased
apoptosis or premature differentiation accounts for the observed
hypoplasia of mPygo2-deﬁcient pancreata. Surprisingly, these defects
were not detected after a speciﬁc deletion of mPygo2 in the
epithelium. Since mPygo2 protein was almost completely absent
from the epithelium of mPygo2Δpan/− embryos at e13.5, we consider it
unlikely that competition by residual wild type cells accounts for the
difference in phenotype. Because the phenotype ofmPygo2−/−mutants
is strikingly similar to the defects associated with perturbations in
mesenchymal signaling, we favor the explanation that mPygo2
controls pancreatic growth indirectly through functions in the
pancreatic mesenchyme. Similar to mPygo2-deﬁciency, lack of
mesenchymal signals results in reduced proliferation of undifferen-
tiated Pdx1+ pancreatic progenitors (Attali et al., 2007; Bhushan et al.,
2001; Pictet and Rutter, 1972). A mesenchymal function for mPygo2 is
also consistent with the observed reduction in endocrine cells in
mPygo2−/− mutants, as signals from the mesenchyme have been
shown to positively inﬂuence the numbers of Ngn3+ precursors and
ﬁnal beta cell numbers (Attali et al., 2007). The speciﬁc effect of
mPygo2 deletion on the beta, delta and PP cell lineages, but not on
alpha cells can be explained by the fact that the speciﬁcation of
glucagon+ cells precedes the time window, during which mPygo2 is
functionally important in the mesenchyme. Consistent with this
notion, it has been shown that Pdx1+ pancreatic progenitors acquire
competence to differentiate into alpha cells as early as e9.5, while
competence to differentiate into the other endocrine cell types is not
acquired until e11.5 (Johansson et al., 2007). Notably, our study does
not entirely exclude the possibility that mPygo2 affects pancreatic
development through functions in endothelial cells. However, we
consider this explanation unlikely, as mPygo2−/− mutants are viable
until birth and vascular defects are associated with early embryonic
lethality (Li et al., 2007; Edsbagge et al., 2005; Esni et al., 2001). Direct
demonstration of a mesenchymal role for mPygo2 will require a Cre-
expressing mouse that speciﬁcally targets the pancreatic mesench-
yme, which is currently not available.
Previous studies have shown that the development of the
pancreatic mesenchyme critically depends on the transcription factors
Isl1 or Pbx1. In the absence of either Isl1 or Pbx1 the pancreatic
mesenchyme is severely hypoplastic, which in turn results in impaired
epithelial growth and differentiation (Ahlgren et al., 1997; Kim et al.,
2002). This phenotype is strikingly different from mPygo2-deﬁcient
embryos, which do not show mesenchymal hypoplasia. Accordingly,
we found that mPygo2 does not control the expression of either Isl1 or
Pbx1. More likely, mesenchymal mPygo2 is required to regulate key
mesenchymal signals that mediate cross talk between mesenchyme
and epithelium. Fibroblast growth factors (FGFs) and epidermal
growth factor (EGF) are two signaling molecules that have been
shown to positively affect progenitor cell proliferation in pancreas
explants in vitro (Cras-Meneur et al., 2001; Elghazi et al., 2002;
Miralles et al., 1999). While analysis of receptor mutants have
conﬁrmed the importance of these signaling pathways for pancreatic
growth in vivo (Miettinen et al., 2000; Pulkkinen et al., 2003), little is
known about which speciﬁc mesenchymal ligand(s) mediate(s) the
response at different developmental stages. One more recentlyidentiﬁed mesenchymal signal is FGF10, which is speciﬁcally
expressed in the pancreatic mesenchyme between e9.5 and e12.5
(Bhushan et al., 2001). Fgf10 mutant embryos display a severe
reduction in the Pdx1+ progenitor cell pool and hypoplastic dorsal
and ventral pancreata (Bhushan et al., 2001). We therefore considered
the possibility that deletion of mPygo2 affects mesenchymal Fgf10
expression, but did not detect a difference in pancreatic Fgf10 mRNA
expression between wild type and mPygo2−/− embryos (data not
shown). It is important to note that the peak of mesenchymal Fgf10
expression precedes the occurrence of pancreatic hypoplasia in
mPygo2-null mutant embryos (Bhushan et al., 2001). Future work
will address which FGFs regulate pancreatic growth at later time
points and whether mPygo2 is involved in regulating their expression.
An important question to consider is whether the pancreatic
defects in mPygo2-deﬁcient embryos are a consequence of perturbed
Wnt signaling or whether mPygo2 possibly has Wnt-independent
functions. Together with previous reports that several Wnt genes,
frizzled receptors and Tcf/Lef transcription factors are expressed in the
pancreatic mesenchyme (Heller et al., 2002; Kim et al., 2005; Lin et al.,
2001), our current ﬁndings in Wnt-reporter mice underscore the
notion that Wnt signaling is active in the mesenchyme. The idea that
mPygo2 may exert its effects by regulating mesenchymal Wnt activity
is consistent with our observation that Wnt-reporter gene activity is
dependent on mPygo2 and that the occurrence of the pancreatic
phenotype in mPygo2−/− mutants coincides with the time point at
which Wnt signaling is most active in the mesenchyme. However, as
the role of mesenchymal Wnt signaling in pancreatic development is
still entirely unknown, understanding of the relationship between
mPygo2 and Wnt signaling will require a better knowledge of
mesenchymal Wnt function.
Notably, Wnt-independent functions for mPygo2 have recently
been described in lens development and have also been noted for
pygopus in Drosophila (Belenkaya et al., 2002; de la Roche and Bienz,
2007; Parker et al., 2002; Song et al., 2007). The broader expression of
mPygo2 compared to the locations ofWnt signaling activity may be an
indication that mPygo2 also has Wnt-independent functions in the
pancreas.
In summary, our study demonstrates thatWnt signaling is active in
the pancreatic mesenchyme during the phase of major pancreatic
growth and differentiation. The combined evidence that this Wnt
activity depends on mPygo2 function and that global, but not pan-
creatic epithelial-speciﬁc deletion of mPygo2 impairs pancreatic
development, points to a possible role of mesenchymal Wnt signaling
in pancreas organogenesis. Since our study is the ﬁrst to identify a
potential function for Wnt in the mesenchyme, additional studies will
be required to fully understand howWnt signaling mediates the cross
talk between the pancreatic mesenchyme and epithelium.
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